Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025
Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.
Melissa BadamoPrint | May 14, 2025
Dr. Rogers shares her career trajectory, what being a doctor is about, and a glimpse of her pet guinea pigs, Maple and Brady.
Nichole TuckerChronic Lymphocytic Leukemia | May 14, 2025
CLL treatment is evolving. Dr. Ryan Jacobs shares why decisions now weigh indefinite therapy vs. time-defined options.
Melissa BadamoAcute Lymphoblastic Leukemia | May 8, 2025
LucyRx’s pharmacy network includes Northwestern Medicine Specialty Pharmacy, Dana Farber Cancer Institute, and more..
Melissa BadamoChronic Lymphocytic Leukemia | May 7, 2025
A pooled analysis of four randomized controlled trials found that statin use was associated with improved OS and PFS.
Andrew MorenoTransplantation & Cellular Therapy | April 25, 2025
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | April 23, 2025
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
Melissa BadamoPrint | April 14, 2025
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Melissa BadamoAcute Lymphoblastic Leukemia | April 8, 2025
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Melissa BadamoChronic Lymphocytic Leukemia | March 19, 2025
Adam Kittai, MD, shares recent studies in CLL he is most excited about, including the AMPLIFY and TRANSCEND 004 trials.
Andrew MorenoChronic Lymphocytic Leukemia | March 7, 2025
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
Melissa BadamoChronic Lymphocytic Leukemia | March 6, 2025
BTKi/BCL2i combinations may change how CLL treatment is offered over a patient’s lifespan, said Kerry Rogers, MD.
Blood Cancer TalksChronic Lymphocytic Leukemia | January 31, 2025
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Andrew MorenoT-Cell Lymphoma | January 30, 2025
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Melissa BadamoChronic Lymphocytic Leukemia | January 29, 2025
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.
Jeff P. Sharman, MDChronic Lymphocytic Leukemia | January 25, 2025
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Jeff P. Sharman, MDChronic Lymphocytic Leukemia | January 24, 2025
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
Melissa BadamoAcute Lymphoblastic Leukemia | January 27, 2025
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Advertisement
Advertisement